Allan F, Watson A, Syme H
J Vet Intern Med. 2024; 38(6):3070-3078.
PMID: 39387578
PMC: 11586580.
DOI: 10.1111/jvim.17212.
Poordast T, Alborzi S, Kiani Z, Omidifar N, Askary E, Chamanara K
Int J Reprod Biomed. 2024; 22(7):567-578.
PMID: 39355309
PMC: 11441281.
DOI: 10.18502/ijrm.v22i7.16970.
Dash S, Nayak M, Samantaray S, Rout N, Ranjit M
J Gastrointest Cancer. 2024; 55(3):1154-1164.
PMID: 38762689
DOI: 10.1007/s12029-024-01045-3.
Meevassana J, Varophas S, Prabsattru P, Kamolratanakul S, Ruangritchankul K, Kitkumthorn N
Sci Rep. 2024; 14(1):7554.
PMID: 38555324
PMC: 10981665.
DOI: 10.1038/s41598-024-58011-z.
Jung M, Song S, Cho S, Shin S, Lee T, Jung W
Breast Cancer Res. 2024; 26(1):31.
PMID: 38395930
PMC: 10885430.
DOI: 10.1186/s13058-024-01784-y.
Exploring Prognostic Immune Microenvironment-Related Genes in Head and Neck Squamous Cell Carcinoma from the TCGA Database.
Li S, Zeng Y, He L, Xie X
J Cancer. 2024; 15(3):632-644.
PMID: 38213736
PMC: 10777048.
DOI: 10.7150/jca.89581.
ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
Cui L, Lu Y, Zheng J, Guo B, Zhao X
J Exp Clin Cancer Res. 2023; 42(1):335.
PMID: 38057867
PMC: 10701957.
DOI: 10.1186/s13046-023-02904-w.
Development and Experimental Validation of a Novel Prognostic Signature for Gastric Cancer.
Liu C, Huo Y, Zhang Y, Yin F, Chen T, Wang Z
Cancers (Basel). 2023; 15(5).
PMID: 36900401
PMC: 10000504.
DOI: 10.3390/cancers15051610.
A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.
Luherne C, Menguy S, Ferte T, Beylot-Barry M, Seneschal J, Milpied B
Acta Derm Venereol. 2022; 102:adv00773.
PMID: 35758515
PMC: 9558750.
DOI: 10.2340/actadv.v102.1062.
Automated Nuclear Segmentation in Head and Neck Squamous Cell Carcinoma Pathology Reveals Relationships between Cytometric Features and ESTIMATE Stromal and Immune Scores.
Blocker S, Cook J, Everitt J, Austin W, Watts T, Mowery Y
Am J Pathol. 2022; 192(9):1305-1320.
PMID: 35718057
PMC: 9484476.
DOI: 10.1016/j.ajpath.2022.06.003.
Determining breast cancer biomarker status and associated morphological features using deep learning.
Gamble P, Jaroensri R, Wang H, Tan F, Moran M, Brown T
Commun Med (Lond). 2022; 1:14.
PMID: 35602213
PMC: 9037318.
DOI: 10.1038/s43856-021-00013-3.
Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.
Khamko R, Wasenang W, Daduang J, Settasatian C, Limpaiboon T
In Vivo. 2022; 36(3):1168-1177.
PMID: 35478117
PMC: 9087092.
DOI: 10.21873/invivo.12816.
Quantitative Measurement of Progesterone Receptor Immunohistochemical Expression to Predict Lymph Node Metastasis in Endometrial Cancer.
Hsiao Y, Fu H, Wu C, Lan J, Ou Y, Tsai C
Diagnostics (Basel). 2022; 12(4).
PMID: 35453837
PMC: 9031886.
DOI: 10.3390/diagnostics12040790.
Comprehensive Characterization of Tumor Purity and Its Clinical Implications in Gastric Cancer.
Lou S, Zhang J, Yin X, Zhang Y, Fang T, Wang Y
Front Cell Dev Biol. 2022; 9:782529.
PMID: 35083216
PMC: 8784737.
DOI: 10.3389/fcell.2021.782529.
Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.
Thanee M, Padthaisong S, Suksawat M, Dokduang H, Phetcharaburanin J, Klanrit P
Cancer Metab. 2021; 9(1):11.
PMID: 33726850
PMC: 7968252.
DOI: 10.1186/s40170-021-00249-6.
Identification of purity and prognosis-related gene signature by network analysis and survival analysis in brain lower grade glioma.
Xiong Z, Xiong Y, Liu H, Li C, Li X
J Cell Mol Med. 2020; 24(19):11607-11612.
PMID: 32869484
PMC: 7576230.
DOI: 10.1111/jcmm.15805.
Comparison of Multiplexed Immunofluorescence Imaging to Chromogenic Immunohistochemistry of Skin Biomarkers in Response to Monkeypox Virus Infection.
Sood A, Sui Y, McDonough E, Santamaria-Pang A, Al-Kofahi Y, Pang Z
Viruses. 2020; 12(8).
PMID: 32717786
PMC: 7472296.
DOI: 10.3390/v12080787.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Bhargava R, Esposito N, OConnor S, Li Z, Turner B, Moisini I
Mod Pathol. 2020; 34(1):77-84.
PMID: 32661297
DOI: 10.1038/s41379-020-0620-2.
Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Cabrera-Galeana P, Soto-Perez-de-Celis E, Reynoso-Noveron N, Villarreal-Garza C, Lara-Medina F, Alvarado-Miranda A
Oncologist. 2020; 25(12):1023-1031.
PMID: 32275801
PMC: 7938403.
DOI: 10.1634/theoncologist.2019-0891.
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.
Bellizzi A
Adv Anat Pathol. 2020; 27(3):114-163.
PMID: 32205473
PMC: 7700753.
DOI: 10.1097/PAP.0000000000000256.